Janney Montgomery Scott LLC Acquires 1,950 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Janney Montgomery Scott LLC increased its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) by 10.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 20,884 shares of the company’s stock after buying an additional 1,950 shares during the period. Janney Montgomery Scott LLC’s holdings in Ventyx Biosciences were worth $729,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of VTYX. Legal & General Group Plc boosted its stake in Ventyx Biosciences by 152.3% during the second quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock worth $30,000 after acquiring an additional 1,462 shares in the last quarter. High Net Worth Advisory Group LLC boosted its stake in Ventyx Biosciences by 100.0% during the third quarter. High Net Worth Advisory Group LLC now owns 1,000 shares of the company’s stock worth $35,000 after acquiring an additional 500 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in Ventyx Biosciences during the second quarter worth about $97,000. American International Group Inc. boosted its stake in Ventyx Biosciences by 102.3% during the second quarter. American International Group Inc. now owns 10,490 shares of the company’s stock worth $128,000 after acquiring an additional 5,305 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. bought a new stake in Ventyx Biosciences during the second quarter worth about $132,000. Institutional investors own 95.57% of the company’s stock.

Ventyx Biosciences Stock Up 0.6 %

Shares of VTYX stock opened at $34.15 on Friday. Ventyx Biosciences, Inc. has a 12 month low of $9.50 and a 12 month high of $41.29. The company has a 50 day simple moving average of $30.39 and a two-hundred day simple moving average of $26.72.

Ventyx Biosciences (NASDAQ:VTYX – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.14). On average, research analysts expect that Ventyx Biosciences, Inc. will post -1.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VTYX has been the topic of several research reports. Morgan Stanley initiated coverage on shares of Ventyx Biosciences in a research note on Thursday, November 17th. They set an “overweight” rating and a $45.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Ventyx Biosciences in a research note on Monday, December 19th. They issued a “buy” rating and a $50.00 target price on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Ventyx Biosciences currently has an average rating of “Buy” and a consensus target price of $49.50.

Insider Buying and Selling at Ventyx Biosciences

In other Ventyx Biosciences news, Director Somu Subramaniam sold 3,935 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $29.08, for a total transaction of $114,429.80. Following the completion of the sale, the director now directly owns 16,888,593 shares of the company’s stock, valued at $491,120,284.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Somu Subramaniam sold 3,935 shares of the stock in a transaction on Monday, November 7th. The shares were sold at an average price of $29.08, for a total value of $114,429.80. Following the completion of the sale, the director now directly owns 16,888,593 shares of the company’s stock, valued at $491,120,284.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Christopher W. Krueger sold 30,000 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $34.46, for a total transaction of $1,033,800.00. Following the completion of the sale, the insider now directly owns 272,692 shares of the company’s stock, valued at $9,396,966.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,173,293 shares of company stock valued at $35,610,353. Insiders own 49.10% of the company’s stock.

About Ventyx Biosciences

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.